We have assembled a team of world experts in cancer immunotherapy to develop therapies that target abnormal proteins called neoantigens, which are produced by cancer cells. Our programs are designed to leverage multiple facets of the immune response to elicit potent immune attack of tumors, with the aim of providing durable response to patients in need.
At Neon we are committed to advancing the field of cancer immunotherapy by investing in research in neoantigen biology, epitope prediction, cancer bioinformatics, personalized therapies and advanced immune profiling of cancer patients.
Headquartered in Cambridge, MA., Neon Therapeutics is a private company launched in 2015 with $55 million in Series A venture capital financing from Third Rock Ventures, Clal Biotechnology Industries and Access Industries.
|HQ||Cambridge, MA, US||Map|
|Employees (est.) (Dec 2019)||71||(-30%)|
Net income (Q1, 2020)
EBIT (Q1, 2020)
When was Neon Therapeutics founded?
Neon Therapeutics was founded in 2015.
Who are Neon Therapeutics key executives?
Neon Therapeutics's key executives are Hugh ODowd, Ed Fritsch and Richard Gaynor.
How many employees does Neon Therapeutics have?
Neon Therapeutics has 71 employees.
Who are Neon Therapeutics competitors?
Competitors of Neon Therapeutics include ImmusanT, Bionuclear and HEALI.
Where is Neon Therapeutics headquarters?
Neon Therapeutics headquarters is located at 40 Erie St #110, Cambridge.
Where are Neon Therapeutics offices?
Neon Therapeutics has an office in Cambridge.
How many offices does Neon Therapeutics have?
Neon Therapeutics has 1 office.
Receive alerts for 300+ data fields across thousands of companies